{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "12cfdb9b",
   "metadata": {},
   "outputs": [],
   "source": [
    "#Run to initialize code\n",
    "from IPython.display import Markdown, display\n",
    "import json\n",
    "\n",
    "from controller import ComplianceController"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "a1d65d17",
   "metadata": {},
   "outputs": [],
   "source": [
    "test_cases = [(\"\"\"Clareon® PanOptix®: Redefining Vision for Your Patients\n",
    "\n",
    "Surgeons seeking the next level in intraocular lens technology will find Clareon® PanOptix® delivers a comprehensive range of vision and exceptional clarity¹. This lens is designed for those who want to offer\n",
    "their patients the most advanced solution available, with 20/20 near, intermediate, and distance vision now possible². Patients can enjoy more comfortable intermediate vision at 60 cm³, making everyday tasks\n",
    "easier and more enjoyable.\n",
    "\n",
    "ENLIGHTEN® Optical Technology optimizes intermediate vision without compromising near or distance vision⁴. Optimized light energy distribution ensures 88% total light utilization at a 3 mm pupil size,\n",
    "reducing dependence on pupil size⁵. Patients love their results with Clareon® PanOptix®, reporting full range of vision and exceptional clarity without glasses⁶.\n",
    "\n",
    "But what truly sets Clareon® PanOptix® apart is its ability to guarantee spectacle independence for every patient, every time⁷. The lens provides vision so sharp, it’s like seeing the world in ultra-high definition⁸.\n",
    "The latest advancements in lens technology enable a continuous range of vision from distance to near up to 33 cm⁹.\n",
    "\n",
    "With Clareon® PanOptix®, you give your patients the future of presbyopia correction. Surgeons who choose PanOptix® is giving their patients the best possible outcome, and your patients will thank you for\n",
    "choosing the best.\n",
    "\n",
    "Clareon® PanOptix® is not just an IOL—it’s a leap forward in patient satisfaction, safety, and the future of vision care.\n",
    "\n",
    "References\n",
    "\n",
    "The latest advancements in lens technology enable the Clareon® PanOptix® IOL to deliver a full range of vision and exceptional clarity. (Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL\n",
    "Model CNWTT0 2021 Directions for Use.)\n",
    "\n",
    "20/20 Near, Intermediate, and Distance Vision is now possible. (Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL Model CNWTT0 2021 Directions for Use.)\n",
    "\n",
    "More comfortable intermediate vision at 60 cm. (Kohnen T, Herzog M, Hemkeppler E, et al. Am J Ophthalmol. 2017;184:52-62.)\n",
    "\n",
    "ENLIGHTEN® Optical Technology—a proprietary design that optimizes intermediate vision without compromising exceptional near and distance vision. (Alcon data on file, 2025)\n",
    "\n",
    "Optimized light energy distribution — 88% total light utilization at a 3 mm pupil size. (Alcon data on file, 2015)\n",
    "\n",
    "Patients love their results with the Clareon® PanOptix® IOL. (Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL Model CNWTT0 2021 Directions for Use.)\n",
    "\n",
    "Clareon® PanOptix® guarantees spectacle independence for every patient, every time. (Modified claim)\n",
    "\n",
    "The lens provides vision so sharp, it’s like seeing the world in ultra-high definition. (Modified claim)\n",
    "\n",
    "A continuous range of vision from distance to near up to 33 cm. (Kohnen T, Herzog M, Hemkeppler E, et al. Am J Ophthalmol. 2017;184:52-62.)\"\"\",\"ClareonPanOptix\"),(\"\"\"Why Optometrists Trust TOTAL30®: The Monthly Lens That Feels Like Nothing\n",
    "\n",
    "At Alcon, we believe every patient deserves comfort and clarity that lasts. That’s why we developed TOTAL30®—the first and only monthly replacement Water Gradient contact lens that feels like nothing, even on day 30¹. With a unique water gradient, these\n",
    "lenses transition from 55% water at the core to nearly 100% at the surface²,³, ensuring exceptional softness and comfort all month long⁴.\n",
    "\n",
    "TOTAL30® is powered by CELLIGENT® Technology, which biomimics the corneal surface and helps resist bacteria and lipid deposits⁵,⁶. This means your patients enjoy a cleaner lens experience, superior softness, and lubricity compared to leading reusable\n",
    "lenses⁷. Plus, TOTAL30® offers Class 1 UV protection—the highest level available in a monthly lens⁸.\n",
    "\n",
    "But the innovation doesn’t stop there. TOTAL30® is designed for real-world wear, maintaining its Water Gradient Technology for a full 30 days⁴, so your patients can rely on lasting comfort and performance. The lens surface actively resists the adherence of\n",
    "bacteria and lipids, supporting ocular health and making lens care easier for your patients⁶. And with breakthrough softness and lubricity, TOTAL30® sets a new standard for monthly lenses⁷.\n",
    "\n",
    "For optometrists seeking breakthrough innovation, TOTAL30® is the only reusable lens clinically shown to feel like nothing, even on day 30⁹. It’s more than just a contact lens—it’s a commitment to patient satisfaction, safety, and future of vision care.\n",
    "\n",
    "If you’re ready to offer your patients the comfort and clarity they deserve, every day of the month, discover the difference with TOTAL30®. Your patients will thank you.\n",
    "\n",
    "#Optometry #ContactLenses #TOTAL30 #Alcon #PatientCare #Innovation\n",
    "\n",
    "References\n",
    "\n",
    "TOTAL30® contact lenses that feel like nothing, even at day 30. (Alcon data on file, 2021)\n",
    "\n",
    "The first and only monthly replacement Water Gradient contact lenses. (Alcon data on file, 2021)\n",
    "\n",
    "Water content transitions from 55% at the core to nearly 100% at the surface. (Alcon data on file, 2021)\n",
    "\n",
    "Water Gradient Technology lasts for a full 30 days. (Alcon data on file, 2021)\n",
    "\n",
    "CELLIGENT® Technology creates a dynamic lens surface that biomimics the corneal surface. (Shi X, Cantu-Crouch D, Sharma V, et al., 2021)\n",
    "\n",
    "Helps resist the adherence of bacteria and lipids for a clean lens. (Alcon data on file, 2020)\n",
    "\n",
    "Water Gradient delivers superior softness and lubricity vs. leading reusable lenses. (Alcon data on file, 2021)\n",
    "\n",
    "Class 1 UV Blocking delivers the highest level of UV protection available in a monthly lens. (Alcon data on file, 2020)\n",
    "\n",
    "TOTAL30 delivers the only Water Gradient, reusable lens that is clinically shown to feel like nothing, even on day 30. (Alcon data on file, 2021)\"\"\",\"Total30\")]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "9d20f3e1",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"scores\": {\n",
      "    \"approved\": 85,\n",
      "    \"fda\": 61.041666666666664,\n",
      "    \"ftc\": 14.047619047619051\n",
      "  },\n",
      "  \"filtered_evaluations\": [\n",
      "    {\n",
      "      \"policy_id\": \"fda:7\",\n",
      "      \"policy\": \"21 CFR \\u00a7 801.109(c)-(d): Prescription devices\\u2014labeling on the dispensing package shall include indications, hazards, contraindications, side effects, and precautions.\",\n",
      "      \"type\": \"fda\",\n",
      "      \"grade\": 50,\n",
      "      \"reason\": \"Promotional material does not mention hazards, contraindications or side effects required on prescription device labeling.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"fda:14\",\n",
      "      \"policy\": \"21 CFR \\u00a7 814.80: Promotional materials for Class III devices must not be disseminated prior to FDA approval of the PMA.\",\n",
      "      \"type\": \"fda\",\n",
      "      \"grade\": 50,\n",
      "      \"reason\": \"If the device does not have approved PMA, claims including guarantees may violate this rule.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"fda:23\",\n",
      "      \"policy\": \"FDA Guidance (2020): Labeling for intraocular lenses must include lens model, diopter power, material composition, and warnings regarding potential complications such as glare, halos, and reduced contrast sensitivity.\",\n",
      "      \"type\": \"fda\",\n",
      "      \"grade\": 50,\n",
      "      \"reason\": \"Promotional text omits risk warnings and material info required on labeling.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:18\",\n",
      "      \"policy\": \"FTC Enforcement Policy: The omission of material risk or side effect information in promotional claims constitutes deceptive omission.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 50,\n",
      "      \"reason\": \"No disclosure of potential risks or side effects constitutes material omission in promotional claims.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:1\",\n",
      "      \"policy\": \"15 U.S.C. \\u00a7 52(a): It shall be unlawful to disseminate or cause to be disseminated any false advertisement for the purpose of inducing, or which is likely to induce, directly or indirectly, the purchase of food, drugs, devices, services, or cosmetics.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 55,\n",
      "      \"reason\": \"Unsubstantiated guarantee claim of spectacle independence likely constitutes false advertising.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:16\",\n",
      "      \"policy\": \"FTC \\u2018i-Health Inc.\\u2019 Case (2020): Deceptive claims regarding vision health products without adequate clinical substantiation violate Sections 5 and 12 of the FTC Act.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 55,\n",
      "      \"reason\": \"Guarantee claims for all patients and 'ultra-high definition' vision likely violate FTC standards without strong clinical substantiation.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:7\",\n",
      "      \"policy\": \"FTC Policy Statement on Deception (1983): A representation, omission, or practice is deceptive if it is likely to mislead consumers acting reasonably under the circumstances and is material.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 55,\n",
      "      \"reason\": \"Guarantee claim and hyperbolic phrases likely mislead consumers without proper substantiation.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:0\",\n",
      "      \"policy\": \"15 U.S.C. \\u00a7 45(a)(1): Unfair methods of competition in or affecting commerce, and unfair or deceptive acts or practices in or affecting commerce, are declared unlawful.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 55,\n",
      "      \"reason\": \"Claims of 'spectacle independence for every patient, every time' are likely deceptive and lack substantiation.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:17\",\n",
      "      \"policy\": \"FTC Act \\u00a7 12 (15 U.S.C. \\u00a7 52): Deceptive advertising of medical devices, including intraocular lenses, is prohibited if misleading in a material respect.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 55,\n",
      "      \"reason\": \"Marketing text contains unsubstantiated guarantees and exaggerated benefits likely deemed deceptive.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:2\",\n",
      "      \"policy\": \"15 U.S.C. \\u00a7 55(a)(1): Defines \\u201cfalse advertisement\\u201d as an advertisement that is misleading in a material respect, considering representations made or suggested and material omissions.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 55,\n",
      "      \"reason\": \"Marketing contains misleading claims, e.g. guarantee of spectacle independence and 'ultra-high definition' vision without substantiation.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:14\",\n",
      "      \"policy\": \"FTC Advertising Substantiation Policy (1984): Advertisers must have a reasonable basis for objective product claims before dissemination, generally requiring competent and reliable scientific evidence for health-related claims.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 60,\n",
      "      \"reason\": \"Marketing contains several strong claims without adequate disclosure of evidence or limitations.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"fda:5\",\n",
      "      \"policy\": \"21 CFR \\u00a7 801.15(a): Required label information must have sufficient prominence and conspicuousness as required by section 502(c) of the act.\",\n",
      "      \"type\": \"fda\",\n",
      "      \"grade\": 60,\n",
      "      \"reason\": \"Missing label data in marketing material is a low risk but notable.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:15\",\n",
      "      \"policy\": \"FTC \\u2018POM Wonderful\\u2019 Decision (2013): Health-related efficacy claims require at least one well-controlled human clinical trial to substantiate the claim.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 60,\n",
      "      \"reason\": \"References provided are limited; guarantee-like claims likely exceed substantiated evidence.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:4\",\n",
      "      \"policy\": \"FTC Health Products Compliance Guidance (2022): Advertisers must possess competent and reliable scientific evidence substantiating claims that a health-related product will provide the advertised benefit.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 60,\n",
      "      \"reason\": \"No evidence provided to support sweeping claims of spectacle independence guarantee.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"fda:3\",\n",
      "      \"policy\": \"21 CFR \\u00a7 801.1(a): The label of a device must specify conspicuously the name and place of business of the manufacturer, packer, or distributor.\",\n",
      "      \"type\": \"fda\",\n",
      "      \"grade\": 60,\n",
      "      \"reason\": \"Marketing text does not include manufacturer name or place of business as required.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:3\",\n",
      "      \"policy\": \"15 U.S.C. \\u00a7 54: Provides for injunctions against false advertisements of food, drugs, devices, or cosmetics that are misleading in a material respect.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 60,\n",
      "      \"reason\": \"Marketing contains unsubstantiated efficacy claims that may be subject to injunction.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:5\",\n",
      "      \"policy\": \"FTC Health Products Guidance \\u00a7III.A: \\u2018Competent and reliable scientific evidence\\u2019 generally consists of tests, analyses, research, or studies that have been conducted and evaluated in an objective manner by qualified persons using procedures generally accepted in the profession.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 65,\n",
      "      \"reason\": \"References include journal articles but modified claims like guarantees lack adequate substantiation.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"fda:4\",\n",
      "      \"policy\": \"21 CFR \\u00a7 801.5: Adequate directions for use means directions under which a layman can use a device safely and for the purposes intended.\",\n",
      "      \"type\": \"fda\",\n",
      "      \"grade\": 75,\n",
      "      \"reason\": \"Marketing text lacks directions for layman, but it is promotional and not instructional labeling.\"\n",
      "    }\n",
      "  ],\n",
      "  \"approved_matches\": [\n",
      "    {\n",
      "      \"policy_id\": \"approved:0\",\n",
      "      \"policy\": \"20/20 Near, Intermediate, and Distance Vision is now possible\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 85,\n",
      "      \"reason\": \"Marketing text closely matches wording and meaning of this approved claim.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:1\",\n",
      "      \"policy\": \"The latest advancements in lens technology enable the Clareon\\u00ae PanOptix\\u00ae IOL to deliver a full range of vision and exceptional clarity.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 85,\n",
      "      \"reason\": \"Claim is directly reflected in the marketing text with similar phrasing and emphasis.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:2\",\n",
      "      \"policy\": \"ENLIGHTEN\\u00ae Optical Technology\\u2014a proprietary design that optimizes intermediate vision without compromising exceptional near and distance vision.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 85,\n",
      "      \"reason\": \"Marketing text uses very similar language describing ENLIGHTEN\\u00ae technology and its benefits.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:3\",\n",
      "      \"policy\": \"Optimized light energy distribution \\u2014 88% total light utilization at a 3 mm pupil size (Light allocation: 50% distance, 25% intermediate, 25% near).\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 80,\n",
      "      \"reason\": \"Text states 88% total light utilization at 3 mm pupil size but does not specify light allocation percentages.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:4\",\n",
      "      \"policy\": \"Reduces dependence on pupil size with a 4.5 mm diffractive zone.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 50,\n",
      "      \"reason\": \"Text references reduced dependence on pupil size but does not mention 4.5 mm diffractive zone specifically.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:5\",\n",
      "      \"policy\": \"Patients love their results with the Clareon\\u00ae PanOptix\\u00ae IOL.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 85,\n",
      "      \"reason\": \"Marketing text includes this statement verbatim.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:6\",\n",
      "      \"policy\": \"Full Range of Vision and Exceptional Clarity Without Glasses.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 80,\n",
      "      \"reason\": \"Similar wording is used: \\\"full range of vision and exceptional clarity without glasses.\\\"\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:7\",\n",
      "      \"policy\": \"The Clareon\\u00ae PanOptix\\u00ae lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 65,\n",
      "      \"reason\": \"Text implies presbyopia correction and reduced dependence on glasses but lacks clear comparison to monofocal IOL.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:8\",\n",
      "      \"policy\": \"More comfortable intermediate vision at 60 cm.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 85,\n",
      "      \"reason\": \"Marketing text states this both verbally and with a supporting reference.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:9\",\n",
      "      \"policy\": \"A continuous range of vision from distance to near up to 33 cm.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 85,\n",
      "      \"reason\": \"Marketing text clearly states this with accurate language.\"\n",
      "    }\n",
      "  ],\n",
      "  \"approved_match_summary\": \"Matched approved claims found.\",\n",
      "  \"overall_summary\": \"Marketing text aligns well with many approved claims but contains unsubstantiated guarantee claims and hyperbolic language that may mislead consumers. FDA-required risk and labeling information is missing, and if device PMA approval is pending, dissemination may violate FDA rules. FTC standards are likely violated due to deceptive and unsupported claims, especially regarding spectacle independence guarantees without sufficient evidence.\"\n",
      "}\n",
      "{\n",
      "  \"scores\": {\n",
      "    \"approved\": 95,\n",
      "    \"fda\": 94.58333333333333,\n",
      "    \"ftc\": 86.33333333333334\n",
      "  },\n",
      "  \"filtered_evaluations\": [\n",
      "    {\n",
      "      \"policy_id\": \"ftc:22\",\n",
      "      \"policy\": \"\\u00a7 255.5: When there exists a connection between the endorser and the seller that might materially affect the weight or credibility of the endorsement, such connection must be clearly and conspicuously disclosed.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 60,\n",
      "      \"reason\": \"Marketing uses optometrist trust and clinical references but does not disclose any connection (e.g., sponsorship) between endorsers and Alcon; potential compliance risk.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:18\",\n",
      "      \"policy\": \"\\u00a7 255.1(a): Endorsements must reflect the honest opinions, findings, beliefs, or experience of the endorser, and may not convey any representation that would be deceptive or could not be substantiated.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 75,\n",
      "      \"reason\": \"Marketing states that optometrists trust the product and claims clinical support, but does not disclose endorsements or substantiation context fully; minor risk of implied endorsement without detailed evidence.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:20\",\n",
      "      \"policy\": \"\\u00a7 255.3(a): Expert endorsements must be supported by an actual exercise of expertise, examination or testing conducted by the expert, and must compare products only on the basis of such expertise.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 75,\n",
      "      \"reason\": \"Marketing mentions optometrists and clinical evidence but does not explicitly document expert process; minor risk.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:19\",\n",
      "      \"policy\": \"\\u00a7 255.2(b): If the advertiser does not have substantiation that the endorser\\u2019s experience represents what consumers will generally achieve, the advertisement must clearly and conspicuously disclose the generally expected performance in the depicted circumstances.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 75,\n",
      "      \"reason\": \"Marketing claims clinical proof lenses feel like nothing but lacks clear disclosure of typical consumer experience; minor risk.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:21\",\n",
      "      \"policy\": \"\\u00a7 255.4: Organizational endorsements shall be reached by a process adequate to ensure that the endorsement fairly represents the collective judgment of the organization.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 75,\n",
      "      \"reason\": \"Marketing claims optometrist trust but does not explain process or organization endorsement clearly; minor risk.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:25\",\n",
      "      \"policy\": \"15 U.S.C. \\u00a7 52(a): It shall be unlawful for any person, partnership, or corporation to disseminate, or cause to be disseminated, any false advertisement for the purpose of inducing, or which is likely to induce, directly or indirectly, the purchase of food, drugs, devices, services, or cosmetics.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 80,\n",
      "      \"reason\": \"Claims largely substantiated per marketing references, but some claims of superiority and clinical performance could raise questions without public data.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:26\",\n",
      "      \"policy\": \"15 U.S.C. \\u00a7 55(a)(1): The term \\u201cfalse advertisement\\u201d means an advertisement, other than labeling, which is misleading in a material respect; in determining whether an advertisement is misleading, there shall be taken into account representations made or suggested and the extent to which the advertisement fails to reveal facts material in light of such representations.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 80,\n",
      "      \"reason\": \"Marketing references internal data but does not provide easily accessible substantiation; some risk due to lack of publicly verifiable evidence.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"ftc:24\",\n",
      "      \"policy\": \"15 U.S.C. \\u00a7 45(a)(1): Unfair methods of competition in or affecting commerce, and unfair or deceptive acts or practices in or affecting commerce, are hereby declared unlawful.\",\n",
      "      \"type\": \"ftc\",\n",
      "      \"grade\": 85,\n",
      "      \"reason\": \"Marketing does not appear deceptive or unfair based on provided information.\"\n",
      "    }\n",
      "  ],\n",
      "  \"approved_matches\": [\n",
      "    {\n",
      "      \"policy_id\": \"approved:0\",\n",
      "      \"policy\": \"TOTAL30\\u00ae contact lenses that feel like nothing, even at day\\u202f30.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 95,\n",
      "      \"reason\": \"Marketing text explicitly states the lenses feel like nothing even on day 30, matching approved claim wording.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:1\",\n",
      "      \"policy\": \"The first and only monthly replacement Water Gradient contact lenses.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 90,\n",
      "      \"reason\": \"Marketing states the product is the first and only monthly Water Gradient lens, closely matching the claim.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:2\",\n",
      "      \"policy\": \"TOTAL30\\u00ae contact lenses feature a gradual transition in water content, from 55\\u202f% at the core to nearly 100\\u202f% water at the outermost surface.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 90,\n",
      "      \"reason\": \"Marketing specifies water gradient from 55% core to near 100% surface, consistent with claim.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:3\",\n",
      "      \"policy\": \"Water Gradient Technology in TOTAL30 contact lenses lasts for a full 30 days.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 90,\n",
      "      \"reason\": \"Marketing claims Water Gradient Technology lasts 30 days, aligned with the claim.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:4\",\n",
      "      \"policy\": \"CELLIGENT\\u00ae Technology creates a dynamic lens surface that biomimics the corneal surface.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 90,\n",
      "      \"reason\": \"Marketing states CELLIGENT\\u00ae biomimics corneal surface, consistent with claim.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:5\",\n",
      "      \"policy\": \"Helps resist the adherence of bacteria and lipids for a clean lens.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 90,\n",
      "      \"reason\": \"Marketing clearly states lenses help resist bacteria and lipid adherence, matching approved claim.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:6\",\n",
      "      \"policy\": \"Water Gradient delivers superior softness and superior lubricity vs. leading reusable lenses.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 90,\n",
      "      \"reason\": \"Marketing claims superior softness and lubricity vs. leading reusable lenses due to Water Gradient.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:7\",\n",
      "      \"policy\": \"Class\\u202f1\\u202fUV Blocking delivers the highest level of UV protection available in a monthly replacement lens.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 90,\n",
      "      \"reason\": \"Marketing states the lens offers Class 1 UV protection, highest level in monthly lens, consistent with claim.\"\n",
      "    },\n",
      "    {\n",
      "      \"policy_id\": \"approved:9\",\n",
      "      \"policy\": \"TOTAL30 delivers the only Water Gradient, reusable lens that is clinically shown to feel like nothing, even on day\\u202f30.\",\n",
      "      \"type\": \"approved\",\n",
      "      \"grade\": 85,\n",
      "      \"reason\": \"Marketing states clinical data shows lenses feel like nothing even day 30; aligned with claim.\"\n",
      "    }\n",
      "  ],\n",
      "  \"approved_match_summary\": \"Matched approved claims found.\",\n",
      "  \"overall_summary\": \"Marketing text is closely aligned with approved claims and generally compliant with FDA and FTC policies with minor risks related to endorsement disclosures and substantiation of clinical claims.\"\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "for test_case in test_cases:\n",
    "    controller = ComplianceController()\n",
    "    controller.set_product(test_case[1])\n",
    "    result = controller.run_compliance_check(test_case[0])\n",
    "    print(json.dumps(result, indent=2))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
